Long-term opioid use for chronic pain can lead to tolerance, misuse, and hyperalgesia, making dose reduction difficult, especially when opioid-use disorder is present. Ketamine, an NMDA receptor antagonist with antihyperalgesic effects, may help. In a historical cohort of 59 chronic pain patients with opioid-use disorder who had failed outpatient tapering, a 5-day hospital stay with low-dose ketamine infusion reduced the average daily opioid dose from 207 mg morphine milligram equivalent to 92 mg at discharge and 103 mg at 12 months. Over half of patients achieved more than 50% tapering immediately, and seven stopped entirely. Ketamine was well tolerated with no significant withdrawal symptoms. Controlled studies are needed to confirm these results.
Psychedelics show promising potential as effective treatments for anxiety and depression, with studies indicating an 80% reduction in symptoms among participants after administration. In a sample of 100 individuals, about 60% reported lasting improvements in mood and anxiety levels six months post-treatment. These findings challenge traditional pharmacology approaches in psychiatry, suggesting that natural compounds could reshape mental health treatment. As political science debates drug regulation, the implications for psychology and pharmacology are profound, opening new avenues for therapeutic exploration.